Loading
A phase 3 trial of Daratumumab, Carfilzomib, Dexamethasone in multiple myeloma, run by AstraZeneca, now recruiting.
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) is a phase 3 interventional study registered as NCT07391657 by AstraZeneca, with 508 participants planned, started 2026-02-23 and due to reach its primary completion in 2028-06-14. Interventions recorded: AZD0120, Daratumumab, Carfilzomib, Dexamethasone, Bortezomib. Conditions listed: Relapsed Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares AZD0120, Daratumumab, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares AZD0120, Relapsed or refractory multiple myeloma, AstraZeneca, Multiple myeloma.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Pomalidomide, Daratumumab, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone.